Neurocrine Biosciences, Inc. (NBIX)
150.66
-5.93
(-3.79%)
USD |
NASDAQ |
Nov 20, 16:00
150.66
0.00 (0.00%)
After-Hours: 19:36
Neurocrine Biosciences Gross Profit (TTM) : 3.569B for Sept. 30, 2026
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 3.569B |
| June 30, 2026 | 3.289B |
| March 31, 2026 | 3.046B |
| December 31, 2025 | 2.808B |
| September 30, 2025 | 2.633B |
| June 30, 2025 | 2.460B |
| March 31, 2025 | 2.359B |
| December 31, 2024 | 2.298B |
| September 30, 2024 | 2.187B |
| June 30, 2024 | 2.062B |
| March 31, 2024 | 1.924B |
| December 31, 2023 | 1.830B |
| September 30, 2023 | 1.728B |
| June 30, 2023 | 1.623B |
| March 31, 2023 | 1.556B |
| December 31, 2022 | 1.450B |
| September 30, 2022 | 1.355B |
| June 30, 2022 | 1.266B |
| March 31, 2022 | 1.180B |
| December 31, 2021 | 1.108B |
| September 30, 2021 | 1.046B |
| June 30, 2021 | 1.011B |
| March 31, 2021 | 1.026B |
| December 31, 2020 | 1.027B |
| September 30, 2020 | 1.024B |
| Date | Value |
|---|---|
| June 30, 2020 | 990.17M |
| March 31, 2020 | 873.35M |
| December 31, 2019 | 776.16M |
| September 30, 2019 | 666.61M |
| June 30, 2019 | 596.95M |
| March 31, 2019 | 511.48M |
| December 31, 2018 | 445.91M |
| September 30, 2018 | 409.71M |
| June 30, 2018 | 319.23M |
| March 31, 2018 | 229.30M |
| December 31, 2017 | 158.68M |
| September 30, 2017 | 64.43M |
| June 30, 2017 | 4.296M |
| March 31, 2017 | -1.713M |
| December 31, 2016 | -1.224M |
| September 30, 2016 | -1.002M |
| June 30, 2016 | -0.838M |
| March 31, 2016 | -0.765M |
| December 31, 2015 | -0.765M |
| September 30, 2015 | -0.719M |
| June 30, 2015 | -0.692M |
| March 31, 2015 | -0.649M |
| December 31, 2014 | -0.827M |
| September 30, 2014 | -0.029M |
| June 30, 2014 | 0.188M |
Gross Profit Definition
Annual, Interim and Preliminary Items - Commercial, Other Financial Companies
Gross Profit (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit (TTM) Benchmarks
| Amgen, Inc. | 28.84B |
| BioCryst Pharmaceuticals, Inc. | 938.98M |
| Halozyme Therapeutics, Inc. | 1.371B |
| Iovance Biotherapeutics, Inc. | 164.64M |
| Precigen, Inc. | 142.20M |